Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,966 DKK | +0.46% | -2.12% | -8.79% |
Apr. 30 | Pfizer, Genmab Say FDA Approves Tivak to Treat Cervical Cancer | MT |
Apr. 30 | Genmab, Pfizer Win US FDA Approval for Cervical Cancer Treatment | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-8.79% | 18.14B | |
-2.96% | 102B | |
+1.97% | 96.09B | |
+2.13% | 22.28B | |
-16.88% | 21.4B | |
-39.98% | 17.02B | |
-14.01% | 16.09B | |
+6.01% | 13.83B | |
+32.53% | 11.97B | |
+313.59% | 8.78B |
- Stock Market
- Equities
- GMAB Stock
- News Genmab A/S
- Morgan Stanley Adjusts Price Target on Genmab to $32 From $33, Maintains Underweight Rating